<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01378715</url>
  </required_header>
  <id_info>
    <org_study_id>EK-134/10</org_study_id>
    <nct_id>NCT01378715</nct_id>
  </id_info>
  <brief_title>Rosuvastatin Pre-Treatment Influences the Risk of Coronary Intervention Study</brief_title>
  <acronym>TIPS-3</acronym>
  <official_title>Rosuvastatin Pre-Treatment Influences the Risk of Percutaneous Coronary Intervention Study (TIPS-3)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Motol</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Motol</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine whether a pre-treatment with high-dose statin (one day
      prior and just before intervention, rosuvastatin 20mg/day) has a positive impact on the
      occurrence of periprocedural myocardial infarction during percutaneous coronary intervention
      (PCI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to attest whether a short-term treatment with high-dose statin (one
      day prior and before intervention, rosuvastatin 20mg/day) can have a positive impact over the
      occurrence of periprocedural myocardial infarction during percutaneous coronary intervention
      (PCI). Patients with stable or unstable (with negative troponin) angina pectoris receiving
      statins (or not, except rosuvastatin 40mg a day) therapy referred for coronary angiography
      and subsequently PCI will be enrolled and randomized (ratio 1:1) to pre-treatment with
      rosuvastatin (20mg 12 hours prior + 20mg immediately before PCI - Rosuvastatin group), or
      immediate PCI (control group). Serum concentration of troponin I will be measured prior to,
      12 hours and 24 hours after PCI.

      Power of study (200 vs 200 pts; p1 = 0.2; p2 = 0.33; alfa = 0.05, n1 = 200, n2 = 200; power
      0.84).

      The primary end-point will be the TnI concentration ≥ 1.5 times the ULN. The secondary
      end-point witl be the TnI concentration ≥ 3 times ULN.

      The Cox regression model will be used to identify the predictors of primary end-points (age,
      diabetes, smoking, symptomatic peripheral artery disease, statin pre-treatment, level of
      total cholesterol, pre-treatment with clopidogrel, multi-vessel disease, unstable angina,
      hs-CRP, therapy with beta-blockers, treatment of complex coronary lesion).

      The patient included shall fulfill all the criteria: 1) significant coronary artery stenosis
      or occlusion indicated for percutaneous coronary intervention and 2) signed informed consent.

      The criteria excluding the inclusion in the study are: 1) positive troponin I (≥ 1 ULN), 2)
      previous inclusion in this study, 3) renal insufficiency, 4) chronic treatment with
      rosuvastatin 40mg or more, and 5) disagreement to be included in this study.

      This study will be multicenter. The Motol University Hospital will participate as the project
      coordinator.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2010</start_date>
  <completion_date type="Anticipated">August 2012</completion_date>
  <primary_completion_date type="Anticipated">June 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>periprocedural myocardial infarction during percutaneous coronary intervention</measure>
    <time_frame>24 hours after PCI</time_frame>
    <description>TnI concentration ≥ 1.5 times the ULN</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>periprocedural myocardial infarction during percutaneous coronary intervention</measure>
    <time_frame>24 hours after PCI</time_frame>
    <description>TnI concentration ≥ 3 times ULN</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with coronary artery disease referred for coronary angiography and subsequently PCI will be enrolled and randomized to pre-treatment with rosuvastatin (20mg 12 hours prior + 20mg immediately prior PCI).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients with coronary artery disease referred for coronary angiography and subsequently PCI will be enrolled and randomized to no-pretreatment with rosuvastatin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>Patients with coronary artery disease referred for coronary angiography and subsequently PCI will be enrolled and randomized to pre-treatment with rosuvastatin (20mg 12 hours prior + 20mg immediately prior PCI).</description>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <other_name>Rosucard (Zentiva, Czech Republic)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  significant coronary artery stenosis or occlusion indicated for percutaneous coronary
             intervention

          -  signed informed consent

        Exclusion Criteria:

          -  positive troponin I (≥ 1 ULN)

          -  previous inclusion in this study

          -  renal insufficiency (creatinine ≥ 200 umol/l)

          -  chronic treatment with rosuvastatin 40mg or more
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Josef Veselka, Prof., MD</last_name>
    <role>Study Chair</role>
    <affiliation>Dpt. of Cardiology, 2nd Medical School of Charles Universty and University Hospital Motol</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Zemanek, MD</last_name>
    <role>Study Director</role>
    <affiliation>Dpt. of Cardiology, 2nd Medical School of Charles Universty and University Hospital Motol</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Zemanek, MD</last_name>
    <phone>+420608921566</phone>
    <email>zejada@seznam.cz</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Josef Veselka, Prof., MD</last_name>
    <phone>+420224434901</phone>
    <email>veselka.josef@seznam.cz</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>1st Medical Dept., Faculty of Medicine in Plzen, Charles University in Prague, University Hospital Plzen</name>
      <address>
        <city>Plzen</city>
        <zip>30100</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Matějovič, Prof., MD</last_name>
      <email>MATEJOVIC@fnplzen.cz</email>
    </contact>
    <investigator>
      <last_name>Martin Matějovič, Prof., MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dpt. of Cardiology, 2nd Medical School of Charles Universty and University Hospital Motol</name>
      <address>
        <city>Prague</city>
        <zip>15006</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Zemanek, MD</last_name>
      <phone>+420608921566</phone>
      <email>zejada@seznam.cz</email>
    </contact>
    <investigator>
      <last_name>Josef Veselka, Prof., MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Zemanek, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dpt. of Cardiology, Hospital Podlesi</name>
      <address>
        <city>Třinec</city>
        <zip>73961</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra Vodzinská, MD</last_name>
      <phone>+420558304404</phone>
      <email>avodzinska@volny.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eastern Slovakia Institute of Cardiovascular Diseases</name>
      <address>
        <city>Kosice</city>
        <zip>04011</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Jankajova, MD</last_name>
      <phone>+4210557891011</phone>
      <email>mjankajova@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Slovakia</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2011</study_first_submitted>
  <study_first_submitted_qc>June 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2011</study_first_posted>
  <last_update_submitted>June 20, 2011</last_update_submitted>
  <last_update_submitted_qc>June 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2011</last_update_posted>
  <responsible_party>
    <name_title>Prof. Jan Trka, MD, PhD</name_title>
    <organization>2nd Medical School of Charles University and University Hospital Motol</organization>
  </responsible_party>
  <keyword>coronary artery disease</keyword>
  <keyword>percutaneous coronary intervention</keyword>
  <keyword>statins</keyword>
  <keyword>periprocedural myocardial infarction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

